Press releases
Here you will find our latest press releases
- Guerbet obtains one million euros of public funding from Bpifrance (France 2030 Investment Plan) for a project developing artificial intelligence for the early detection of pancreatic cancer
- Guerbet announces U.S. Food And Drug Administration (FDA) approval of Elucirem
- 2022 Half Year Results
- H1 2022 Sales
- Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
Media resources
Feel free to download the files you need.
Media relations contact
Actifin is our media relations agency and Mathias Jordan will take care of your request.
+33 (0)1 56 88 11 26